Download Slides - Medi-Span

Redefining MTM for the New Era of Healthcare
Today’s webinar is sponsored by
Wolters Kluwer Health Clinical Drug Information
Medi-Span®, Lexicomp®, Facts & Comparisons®
Who we are:
 Medi-Span - Embedded drug databases used in 60 EMRs, 1,000+ hospitals, and
37,000 retail pharmacies
 Lexicomp - Referential drug information used in nearly 2,000 hospitals and by
80,000 mobile users
 Facts & Comparisons - Used in over 27,000 retail locations by more than 70,000
pharmacists
Dedicated to building innovative and trusted resources in multiple formats for use in
any setting, WKH Drug Information Solutions aim to lessen system-wide costs while
helping reduce errors, assist in improving patient safety and creating practical drug
information solutions to increase workflow efficiency throughout the continuum of
care.
Confidential and Proprietary - Copyright 2014 Wolters Kluwer Health
Our Speaker
Brian J. Isetts, RPh, PhD, BCPS, FAPhA
Professor, University of Minnesota
College of Pharmacy
• Professor at the University of Minnesota College
of Pharmacy and a consultant pharmacist.
• He recently returned from a three-year
sabbatical serving as a Health Policy Fellow at
the Centers for Medicare & Medicaid Services in
the CMS Part D MTM Program and at the CMS
Innovation Center.
Confidential and Proprietary - Copyright 2014 Wolters Kluwer Health






8












12
Sharon and Edward Jungbauer


•
•
17
A Three-Part Aim
Better Health for
the Populations
Better Care
for Individuals
18
Lower Cost
Through
Improvement




19




















CPT-MTMS PATIENT CARE PROCESS
ESTABLISH A THERAPEUTIC RELATIONSHIP
ASSESSMENT
What does
my patient
want and
need?
CARE PLAN
EVALUATION
What am I
going to do
with and for
my patient?
How will we
know if it is
working?
Continuous Follow Up
24















28






29
Medicare FFS 30-Day All-Cause Readmission Rates
-- Unprecedented National Decreases --




Value Pre- AIM
Team
Percent of Patients with INR > 4
% of patients with INR >4
9%
8%
7%
6%
5%
4%
3%
2%
1%
0%
Inpatie…
Month
Ascension Health:
Progress in Reducing the Number
of INRs greater than 5
33























40


Please type your questions in the chat window
For More Information
Michelle Curren
Market Manager
Wolters Kluwer Health
Lexicomp | Medi-Span | Facts & Comparisons
[email protected]
Follow @Medispan or
@Lexi_Comp on Twitter
to learn about upcoming
webinars!
Confidential and Proprietary - Copyright 2014 Wolters Kluwer Health
Notice
This presentation may not be copied, reproduced, redistributed or otherwise transmitted in any
form or by any means, in whole or in part, without prior written consent from Wolters Kluwer
Health. Any unauthorized use of copyrighted material incorporated within this presentation will
be subject to legal action. The content in this presentation has been prepared strictly for
informational purposes only, and is not intended or offered as legal advice. Although the
information provided is believed to be reliable and accurate, all information is without
warranties of any kind, either express or implied, including but not limited to warranties of the
accuracy, currency, completeness of information, or the suitability of the information for any
particular purpose. Wolters Kluwer Health shall not be liable for any direct, indirect, incidental,
special, consequential, punitive or any other damages arising out of the use of any information
discussed in this presentation. In deciding your organization’s specific technology, business and
legal requirements, you must not rely on the information in this presentation as a substitute
to advice from your own legal counsel.
Confidential and Proprietary - Copyright 2014 Wolters Kluwer Health
45

Download Report